DexCom, Inc. $DXCM Shares Sold by Banco Santander S.A.

Banco Santander S.A. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 1.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,248 shares of the medical device company’s stock after selling 2,060 shares during the quarter. Banco Santander S.A.’s holdings in DexCom were worth $16,956,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of DXCM. Brighton Jones LLC grew its stake in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in DexCom by 936.3% in the first quarter. Robeco Institutional Asset Management B.V. now owns 236,284 shares of the medical device company’s stock valued at $16,136,000 after purchasing an additional 213,483 shares during the period. Diversified Trust Co boosted its holdings in DexCom by 12.0% in the first quarter. Diversified Trust Co now owns 19,435 shares of the medical device company’s stock valued at $1,327,000 after purchasing an additional 2,078 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in DexCom by 20.7% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 178,538 shares of the medical device company’s stock valued at $12,107,000 after purchasing an additional 30,627 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,383 shares of company stock valued at $434,274 over the last quarter. Company insiders own 0.32% of the company’s stock.

DexCom Stock Down 1.0%

Shares of NASDAQ DXCM opened at $70.33 on Monday. The company has a market capitalization of $27.58 billion, a price-to-earnings ratio of 48.84, a price-to-earnings-growth ratio of 1.48 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business has a 50-day moving average of $72.37 and a two-hundred day moving average of $77.98. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DXCM. Canaccord Genuity Group reiterated a “buy” rating and issued a $106.00 target price on shares of DexCom in a report on Monday, September 29th. Cowen reiterated a “buy” rating on shares of DexCom in a report on Friday. Argus began coverage on DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a report on Friday. Finally, The Goldman Sachs Group decreased their target price on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.19.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.